文献速递免疫规划妇幼与学校卫生

阿布达拉新冠亚单位疫苗在儿童和青少年中的有效性与安全性:一项开放标签、单臂、2期试验(MEÑIQUE)

Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE).
PubMed 文献 · Vaccine · 2024-08-15

该2期开放标签单臂试验纳入703名3-18岁受试者,按0-14-28天程序肌注阿布达拉疫苗,主要终点为安全性和与成人(19-21岁)的中和抗体免疫桥接非劣效分析。不良事件报告率为264/703(37.6%),多为注射部位轻度反应,未报告严重不良事件。儿童和青少年GMT比值及血清反应率差异均满足非劣效标准,结论认为疫苗安全、免疫原性良好,并基于非劣效分析推断其有效性。

要点

  • 阿布达拉疫苗在3-18岁儿童和青少年中安全,不良事件多为注射部位轻度反应。
  • 儿童(3-11岁)与成人中和抗体GMT比值为0.87(95%CI 0.69-1.08),下限高于0.67。
  • 青少年(12-18岁)与成人GMT比值为1.07(95%CI 0.82-1.39),血清反应率差异为-3%(-7%,1%)。

核心结论

  • 阿布达拉疫苗在3-18岁儿童和青少年中安全且具有免疫原性,基于非劣效分析推断其有效性。
  • 该疫苗适合纳入大规模疫苗接种策略,因成人和儿童使用相同疫苗强度(RBD 50 μg)和接种程序,且易于在2-8°C储存和处理。

研究设计与样本

  • 2期、开放标签、单臂临床试验,纳入3-18岁受试者,按0-14-28天程序肌注阿布达拉疫苗。
  • 主要终点为安全性和与成人(19-21岁)的中和抗体免疫桥接非劣效分析。
  • 试验在古巴公共临床试验注册中心注册,注册号RPCEC00000390。

主要发现

  • 2021年9月13日至9月17日共纳入703名参与者,当时主要流行SARS-CoV-2 Delta变异株。
  • 发生不良反应的人数为264/703(37.6%),不良反应多为轻度且发生在注射部位,在最初24-48小时内缓解,未报告严重不良事件。
  • 297名儿童(3-11岁)与297名成人比较,SARS-CoV-2中和抗体GMT比值为0.87(95%CI 0.69-1.08)。
  • 203名青少年(12-18岁)与203名成人比较,中和抗体GMT比值为1.07(95%CI 0.82-1.39)。
  • 两个年龄组GMT下限均高于0.67;儿童血清反应率差异为1%(-2%,4%),青少年为-3%(-7%,1%),均高于-10%。

关键数值与推荐

  • 非劣效标准:GMT比值下限高于0.67,血清反应率差异下限高于-10%。
  • 儿童(3-11岁)GMT比值0.87(95%CI 0.69-1.08),血清反应率差异1%(-2%,4%)。
  • 青少年(12-18岁)GMT比值1.07(95%CI 0.82-1.39),血清反应率差异-3%(-7%,1%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives We evaluated the safety, immunogenicity and efficacy of Abdala, a protein subunit vaccine for 2019 coronavirus disease (COVID-19), in children and adolescents. Methods A phase 2, open-label, single-arm clinical trial was carried out. Subjects aged 3 to 18 years were eligible. Abdala vaccine was administered intramuscularly at 0-14-28 days. The main endpoints were safety and the immunobridging analysis with a non-inferiority design, to infer the efficacy of the vaccine in paediatric population based on the comparison of neutralizing antibodies (NAb) to SARS-CoV-2, with adults (19-21 years). The trial is registered with the Cuban Public Registry of Clinical Trials, RPCEC00000390. Results From September 13th to September 17th, 2021, 703 participants were included in the context of a predominantly SARS-CoV-2 Delta variant circulation. The number of individuals who experienced adverse reactions was 264/703 (37·6%). Adverse reactions were mostly mild and occurred at the injection site, which resolved within the first 24-48 h. There were no reports of severe adverse events. For the non-inferiority comparison of 297 children (3-11 years) with 297 adults, the geometric mean (GMT) ratio of SARS-CoV-2 NAb was 0·87 (95% CI 0·69-1·08) and 1·07 (0·82-1·39) in the same comparison for 203 adolescents (12-18 years) and 203 adults. For both age groups, the lower limit of GMT was higher than 0·67. The differences in seroresponse rates of Nab for children were 1% (-2%, 4%) and -3% (-7%, 1%) for adolescents, higher than -10% in both age groups. Conclusions The Abdala vaccine was safe and immunogenic in a paediatric population aged 3-18 years, with inferred efficacy based on non-inferior analysis. The vaccine is very suitable to fit into massive vaccination strategies, considering the advantages of using the same vaccine strength (RBD 50 μg) and schedule of administration for both adults and children, as well as the easy storage and handling conditions at 2-8 °C.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hernández-Bernal F, Noa-Romero E, Quintana-Guerra J, et al. Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE). Vaccine. 2024. PMID: 39151232. doi:10.1016/j.vaccine.2024.126223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。